Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 5 studies | 24% ± 8% | |
| epithelial cell | 4 studies | 21% ± 3% | |
| astrocyte | 3 studies | 28% ± 9% | |
| oligodendrocyte | 3 studies | 22% ± 4% | |
| interneuron | 3 studies | 37% ± 20% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 31% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| bladder | 100% | 727.62 | 21 / 21 | 100% | 6.84 | 504 / 504 |
| esophagus | 100% | 534.53 | 1445 / 1445 | 100% | 3.99 | 183 / 183 |
| intestine | 100% | 590.81 | 966 / 966 | 100% | 6.51 | 527 / 527 |
| ovary | 100% | 954.28 | 180 / 180 | 100% | 4.77 | 430 / 430 |
| skin | 100% | 830.78 | 1809 / 1809 | 100% | 5.67 | 472 / 472 |
| uterus | 100% | 769.26 | 170 / 170 | 100% | 5.32 | 459 / 459 |
| thymus | 100% | 679.89 | 653 / 653 | 100% | 4.84 | 604 / 605 |
| breast | 100% | 777.28 | 459 / 459 | 100% | 6.03 | 1116 / 1118 |
| prostate | 100% | 630.40 | 245 / 245 | 100% | 4.75 | 501 / 502 |
| stomach | 100% | 452.71 | 358 / 359 | 100% | 5.73 | 286 / 286 |
| kidney | 100% | 534.36 | 89 / 89 | 99% | 3.60 | 894 / 901 |
| pancreas | 99% | 364.25 | 325 / 328 | 100% | 6.66 | 178 / 178 |
| lung | 99% | 462.46 | 573 / 578 | 100% | 4.08 | 1152 / 1155 |
| adrenal gland | 100% | 620.97 | 258 / 258 | 99% | 3.75 | 227 / 230 |
| brain | 98% | 442.80 | 2597 / 2642 | 100% | 5.30 | 705 / 705 |
| liver | 99% | 290.20 | 224 / 226 | 96% | 2.44 | 389 / 406 |
| adipose | 100% | 677.43 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 8.11 | 29 / 29 |
| spleen | 100% | 719.93 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 4.98 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.66 | 1 / 1 |
| blood vessel | 100% | 528.39 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 99% | 355.38 | 795 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 99% | 3.39 | 79 / 80 |
| heart | 98% | 383.53 | 843 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 79% | 372.60 | 738 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0032049 | Biological process | cardiolipin biosynthetic process |
| GO_0016024 | Biological process | CDP-diacylglycerol biosynthetic process |
| GO_0031314 | Cellular component | extrinsic component of mitochondrial inner membrane |
| GO_0005743 | Cellular component | mitochondrial inner membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0004605 | Molecular function | phosphatidate cytidylyltransferase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TAMM41 |
| Protein name | Phosphatidate cytidylyltransferase, mitochondrial (EC 2.7.7.41) (CDP-diacylglycerol synthase) (Mitochondrial translocator assembly and maintenance protein 41 homolog) Chromosome 3 open reading frame 31, isoform CRA_e (Phosphatidate cytidylyltransferase, mitochondrial) (TAM41 mitochondrial translocator assembly and maintenance homolog) Phosphatidate cytidylyltransferase, mitochondrial (EC 2.7.7.41) (CDP-diacylglycerol synthase) (CDP-DAG synthase) (Mitochondrial translocator assembly and maintenance protein 41 homolog) (TAM41) |
| Synonyms | hCG_28045 C3orf31 |
| Description | FUNCTION: Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol. . FUNCTION: Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol. . FUNCTION: Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol. . FUNCTION: Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol. . |
| Accessions | A0A0G2JQ92 ENST00000623389.1 ENST00000414736.1 ENST00000624236.3 ENST00000455809.6 [Q96BW9-3] ENST00000624386.3 ENST00000630055.1 ENST00000273037.9 [Q96BW9-2] H7C1A2 ENST00000624342.1 ENST00000623275.3 ENST00000444133.6 [Q96BW9-1] ENST00000457498.5 ENST00000417723.1 Q96BW9 ENST00000625087.2 ENST00000623848.2 ENST00000411947.1 G3V0F3 B4E101 ENST00000630288.1 |
